Hamada Tsuyoshi, Keum NaNa, Nishihara Reiko, Ogino Shuji
Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, 450 Brookline Ave., Room SM1036, Boston, MA, 02215, USA.
Department of Nutrition, Harvard T.H. Chan School of Public Health, Boston, MA, USA.
J Gastroenterol. 2017 Mar;52(3):265-275. doi: 10.1007/s00535-016-1272-3. Epub 2016 Oct 13.
Molecular pathological epidemiology (MPE) is an integrative field that utilizes molecular pathology to incorporate interpersonal heterogeneity of a disease process into epidemiology. In each individual, the development and progression of a disease are determined by a unique combination of exogenous and endogenous factors, resulting in different molecular and pathological subtypes of the disease. Based on "the unique disease principle," the primary aim of MPE is to uncover an interactive relationship between a specific environmental exposure and disease subtypes in determining disease incidence and mortality. This MPE approach can provide etiologic and pathogenic insights, potentially contributing to precision medicine for personalized prevention and treatment. Although breast, prostate, lung, and colorectal cancers have been among the most commonly studied diseases, the MPE approach can be used to study any disease. In addition to molecular features, host immune status and microbiome profile likely affect a disease process, and thus serve as informative biomarkers. As such, further integration of several disciplines into MPE has been achieved (e.g., pharmaco-MPE, immuno-MPE, and microbial MPE), to provide novel insights into underlying etiologic mechanisms. With the advent of high-throughput sequencing technologies, available genomic and epigenomic data have expanded dramatically. The MPE approach can also provide a specific risk estimate for each disease subgroup, thereby enhancing the impact of genome-wide association studies on public health. In this article, we present recent progress of MPE, and discuss the importance of accounting for the disease heterogeneity in the era of big-data health science and precision medicine.
分子病理流行病学(MPE)是一个综合性领域,它利用分子病理学将疾病过程中的个体间异质性纳入流行病学研究。在每个个体中,疾病的发生和发展由外源性和内源性因素的独特组合决定,从而导致疾病的不同分子和病理亚型。基于“独特疾病原则”,MPE的主要目标是揭示特定环境暴露与疾病亚型之间在决定疾病发病率和死亡率方面的交互关系。这种MPE方法可以提供病因和发病机制方面的见解,有可能为个性化预防和治疗的精准医学做出贡献。尽管乳腺癌、前列腺癌、肺癌和结直肠癌一直是研究最为普遍的疾病,但MPE方法可用于研究任何疾病。除分子特征外,宿主免疫状态和微生物组谱可能影响疾病进程,因此可作为有用的生物标志物。因此,已经实现了将多个学科进一步整合到MPE中(例如,药物MPE、免疫MPE和微生物MPE),以提供对潜在病因机制的新见解。随着高通量测序技术的出现,可用的基因组和表观基因组数据大幅增加。MPE方法还可以为每个疾病亚组提供特定的风险估计,从而增强全基因组关联研究对公共卫生的影响。在本文中,我们介绍了MPE的最新进展,并讨论了在大数据健康科学和精准医学时代考虑疾病异质性的重要性。